RESULTS: eGFR estimates by the new equations correlated significantly with eGFR estimates from previous equations, with the best correlation observed between the 2 equations containing cystatin C [intraclass correlation coefficient 0.95 (95% confidence interval 0.94 -0.95)]. During a median follow-up of 3.94 years, 371 patients died. The Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) equations containing cystatin C were found to be best for predicting death [area under the ROC curve 0.685 for CKD-EPI-cystatin C and 0.672 for CKD-EPIcreatinine-cystatin C vs 0.632 for simplified Modification of Diet in Renal Disease Study traceable to isotope dilution mass spectrometry and 0.643 for CKD-EPI (all P Ͻ 0.001)]. The CKD-EPI-cystatin C equations also showed significantly better calibration and reclassification measurements for both integrated discrimination improvement and net reclassification improvement in predicting death (P Ͻ 0.001). Reclassification with these new equations was particularly better in the subgroup with intermediate eGFR [45-74 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 ].
CONCLUSIONS:
The two new CKD-EPI equations containing cystatin C are useful for HF risk stratification and show better prognostic performance than creatinine-only based eGFR equations, mostly in patients with intermediate eGFR. These equations seem appropriate for assessing prognosis of HF patients with moderate renal insufficiency.
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Renal insufficiency frequently occurs in conjunction with heart failure (HF) 6 and worsens patient prognosis (1) (2) (3) . The correct estimation of renal function may be crucial to assessing prognosis in patients with HF. Several equations based on measured glomerular filtration rate or creatinine clearance have been developed and are used in routine clinical practice to calculate the estimated glomerular filtration rate (eGFR) to determine renal insufficiency; the best-known equations are the Cockcroft-Gault (C-G) equation (4 ) , the simplified Modification of Diet in Renal Disease (MDRD-4) equation (5 ) , and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (6 ) . We previously compared C-G with MDRD-4 and CKD-EPI in patients with HF and found that the C-G equation was a better prognosticator than the other 2 routinely used eGFR equations (7 ) .
In the last several years, cystatin C has emerged as a novel renal biomarker with prognostic implications in patients with acute HF and has been reported to provide a more accurate and precise estimate of GFR than serum creatinine (8 -12 ) . Standardization of creatinine assays has substantially modified the accuracy of the equations, and C-G likely will not be used in the future. To account for creatinine measurements that are traceable to isotope dilution mass spectrometry (IDMS), MDRD-4 has been modified to MDRD-4-IDMS (13 ) . Recently, 2 new equations for eGFR that use cystatin C (CKD-EPI-cystatin C) and combined creatinine and cystatin C (CKD-EPI-creatinine-cystatin C) concentrations were proposed (14 ) . To the best of our knowledge, the utility of these equations has not been assessed in patients with HF. Accordingly, we aimed to assess the prognostic role of eGFR calculated with these new equations in a population of outpatients with HF over a long-term follow-up. We also analyzed the agreement between them and MDRD-4-IDMS and CKD-EPI and compared their predictive ability for long-term mortality.
Methods

STUDY POPULATION
From May 2006 to July 2010, ambulatory patients treated at a multidisciplinary HF unit were included consecutively in the study. Patients were referred to the unit by the cardiology or internal medicine departments and, to a lesser extent, by the emergency or other hospital departments. The principal referral criteria were HF according to the European Society of Cardiology guidelines irrespective of etiology and at least 1 HF hospitalization and/or documented reduced left ventricular ejection fraction (LVEF). Blood samples were obtained by venipuncture between 0900 and 1200 during conventional ambulatory visits, and adequately centrifuged serum samples were stored at Ϫ80°C. Both cystatin C and creatinine concentrations were analyzed from the same blood sample.
All participants provided written informed consent, and the local ethics committee approved the study. All study procedures were in accordance with the ethical standards outlined in the Helsinki Declaration of 1975 as revised in 1983.
FOLLOW-UP AND OUTCOMES
All patients were followed at regular predefined intervals, with additional visits as required in cases of decompensation. The regular visitation schedule included a minimum of quarterly visits with nurses, biannual visits with physicians, and elective visits with geriatricians, psychiatrists, and rehabilitation physicians (7, 15 ) . Patients who did not attend the regular visits were contacted by telephone.
Death from all causes was the main outcome. Fatal events were identified from the clinical records of the HF unit, other hospital wards, the emergency room, and general practitioners, and by contacting the patients' relatives. The data were verified with the databases of the regional and national health systems. 
CREATININE AND CYSTATIN C ASSAYS
ESTIMATION OF GFR
eGFR was calculated with (a) the MDRD-4-IDMS equation for standardized creatinine (13 ); (b) the CKD-EPI equation (6 ); (c) the CKD-EPI-cystatin C equation (14 ) ; and (d) the CKD-EPI-creatininecystatin C equation (14 ) .
STATISTICAL ANALYSIS
Intraclass correlation coefficients (ICCs) were calculated between pairs of continuous variables, and Cohen's index was calculated for categorical variables. Mean differences between scores and 95% limits of agreement were analyzed by the BlandAltman method (17 ) . To compare ICCs and values between pairing methods, we used bootstrap methods with 10 000 replicates. Survival analyses were performed with Cox regression analyses that incorporated the following variables: age; sex; New York Heart Association (NYHA) functional class; ischemic etiology of HF; LVEF (in %); HF duration; presence of diabetes mellitus, chronic obstructive lung disease, and peripheral artery disease; plasma hemoglobin (g/dL); serum sodium (mmol/L); beta-blocker treatment; and ACE inhibitor or angiotensin II receptor blocker treatment, together with eGFR [in mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 ] categories, calculated with the 4 equations. Kaplan-Meier survival curves were plotted for eGFR National Kidney Foundation subgroup distributions based on the 4 equations and were statistically compared by obtaining a P value with 10 000 bootstrapping replicates.
All analyses were performed with the software R (version 2.11.1) statistical package (Foundation for Statistical Computing). We used different measurements of performance to test the potential incremental prognostic value for risk of death of the 4 eGFR equations.
Discrimination. The area under the ROC curve (AUC) summarized the diagnostic discrimination. Discrimination refers to a model's ability to distinguish correctly between 2 classes of outcomes. We used the index of rank correlation, Somers D, which incorporates information from censored data. AUCs between models were compared with 10 000 bootstrapping replicates.
Calibration. The D'Agostino-Nam version of the Hosmer-Lemeshow calibration test was used to calculate 2 values. A model is considered to be well calibrated when predicted and observed values agree for any reasonable grouping of the observation (no significant differences in the Hosmer-Lemeshow test). In addition, the Bayesian information criterion (BIC), the Akaike information criterion (AIC), and the Brier score were calculated for each model. Given any 2 estimated models, the model with the lower BIC, AIC, and Brier scores was preferred. There are no statistical tests to compare different BIC, AIC, or Brier estimations; however, lower values indicate a better model.
Reclassification. We used the method described by Pencina et al. (18 ) . Two main statistics are used to assess reclassification. The integrated discrimination improvement (IDI) considers changes in the estimated mortality prediction probabilities as a continuous variable. P values of Ͻ0.05 from 2-sided tests were considered significant. The net reclassification improvement (NRI) requires a previous definition of meaningful risk categories (we used tertiles for the risk of death: Ͻ18.5%, 18.5%-41%, and Ͼ41%). The NRI considers changes in the estimated mortality prediction probabilities that imply a change from 1 category to another.
Results
Of the 891 consecutive patients included from May 2006 to July 2010, eGFR calculated by MDRD-4 IDMS, CKD-EPI, CKD-EPI-cystatin C, and CKD-EPI-creatinine-cystatin C equations was available for 879 patients, who were included in this analysis. The median age of the patients was 70.4 years (interquartile range, 60.5-77.2 years). Table 1 ] was quite similar according to the different equations: 64.1% with MDRD-4-IDMS, 61.9% with CKD-EPI, 64.0% with CKD-EPIcystatin C, and 62.1% with CKD-EPI-creatinine-cystatin C. However, the distribution of patients among National Kidney Foundation categories according to the 2 equations was different when the 4 groups were considered (see online Supplemental Table 1) .
SURVIVAL, CALIBRATION, DISCRIMINATION, AND
RECLASSIFICATION
During a median follow-up period of 3.94 years, 371 patients died. Fig. 1, A-D , depicts the Kaplan-Meier survival curves according to eGFR subgroups as estimated by the 4 equations. All equations could significantly differentiate survival among the eGFR subgroups (P Ͻ 0.001). However, there were statistically significant differences between the 2 equations containing cystatin C and the creatinine-only based equations (P Ͻ 0.001 in all cases), whereas no significant difference was seen between the 2 equations containing cystatin C (P ϭ 0.792). Fig. 2 Ϫ1 calculated with the 2 equations containing cystatin C ( Table 2 ).
In Tables 3 and 4 the performance for risk of death prediction of CKD-EPI-cystatin C and CKD-EPIcreatinine-cystatin C with the other 2 equations at 4 years of follow-up is compared. The new CKD-EPI equations containing cystatin C showed better discrimination, calibration, and reclassification measurements, both IDI and NRI, for risk of death. For CKD-EPIcystatin C, net reclassification improvement was 23.2 (14.9; 31.6) and 18.6 (10.6; 26.7) vs MDRD-4-IDMS and CKD-EPI, respectively; for CKD-EPI-creatinine-cystatin C, net reclassification improvement was 15.7 (9.4; 22.0) and 11.0 (5.2; 16.8), respectively (all P Ͻ 0.001). ] (see online Supplemental Table 2 ). When comparing both new equations, CKD-EPI-cystatin C performed globally better than CKD-EPI-creatinine-cystatin C for the total cohort, but showed similar performance in the subset of patients with eGFR between 45 and 74.9 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 (see online Supplemental Table 3 ).
Discussion
eGFR equations are useful not only to assess renal function but also to stratify prognosis. We recently reported that the C-G equation predicted long-term mortality better than the MDRD-4 or CKD-EPI equations in a cohort of patients with chronic HF (7 ). However, standardization of creatinine assays has substantially modified accuracy of the equations, and C-G will probably not be used in the future. Cystatin C has emerged as a novel renal biomarker with prognostic implications in HF patients (8 -12 ) and fewer confounding factors than serum creatinine. We have previously compared the long-term prognostic value of cystatin C concentrations and eGFR by C-G. eGFR calculated with the C-G equation and cystatin C had similar long-term predictive value in a real-life ambulatory HF population, although reclassification was poorer with cystatin C as measured by IDI and NRI (15 ) . Remarkably, cystatin C improved risk stratification in patients with eGFR between 30 and 60 mL ⅐ min
, which is in agreement with previous reports that included patients with acute decompensated HF (9 ) . All equations that rely on serum creatinine are subject to the same bias as creatinine values, especially in overweight and underweight patients, in whom muscle mass can influence serum creatinine. Moreover, chronic diseases (such as HF) may affect both muscle mass and creatinine metabolism. The new CKD-EPI-cystatin C and CKD-EPI-creatinine-cystatin C equations, which were recently developed to address this problem, have been found to be more accurate than conventional CKD-EPI for estimating GFR, especially in patients with eGFR between 45 and 75 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 (14 ) . In the current study, in a cohort of HF patients who had a high prevalence of renal failure, we assessed the prognostic value of the 2 new CKD-EPI equations and compared them with the previously used MDRD-4-IDMS and CKD-EPI equations. Both the CKD-EPI-cystatin C and the CKD-EPIcreatinine-cystatin C equation yielded better measurements of performance (discrimination, calibration, and reclassification); this suggests that estimating renal function with these new equations in HF patients may be preferred. However, considering the expense and limited availability of cystatin C assays in routine laboratories, one should balance the cost and benefits of applying the new equations, as the other 2 equations also independently predict survival, as assessed by Kaplan-Meier survival curves. As the authors of the new equations have stated, the use of cystatin C could increase laboratory costs, and its use should probably be prioritized for those patients with moderate renal insufficiency. Indeed, in our study, the NRI of the new equations for patients with eGFR between 45 and 74.9 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 increased to 30.1% vs MDRD-4-IDMS and 25.2% vs CKD-EPI for CKD-EPI-cystatin C and to 31.1% vs MDRD-4-IDMS and 28.2% vs CKD-EPI for CKD-EPI-creatinine-cystatin C. This concurs with our previous study, where cystatin C alone also improved risk stratification in patients with eGFR C-G values of between 30 and 60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 (15 ) , and also is in concordance with the original description of the equation, where 19.4.% of patients with an eGFR based on creatinine between 45 and 74 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 were reclassified correctly as either Ͻ60 or Ն60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 with the CKD-EPI-creatininecystatin C equation. It is reasonable to speculate that better reclassification on renal function will lead to a better reclassification in prognosis. In this HF cohort, the CKD-EPI-cystatin C equation performed somewhat better than the CKD-EPIcreatinine-cystatin C equation for predicting risk of death, despite the fact that in the original paper where these equations were described, the latter was more accurate in estimating GFR (in non-HF patients). Interestingly, however, our data concur with recent observations by Shlipack et al. (19 ) , who also found less NRI prognostic improvement for the creatinine-cystatin C equation over the cystatin-only equation. As Shlipack et al. (19 ) discuss in their paper, it is possible that the non-GFR-confounding determinants of creatinine in persons who are most susceptible to illness-and such is the case in HF patients-may particularly weaken the association between eGFR based on combined measurements (creatinine-cystatin C) or that alternatively, if nondeterminants of cystatin C augment its association with the risk of death, then they will have a greater effect on the cystatin C-based eGFR than on the eGFR that is based on combined creatininecystatin C measurements.
LIMITATIONS
This study only compared equations of estimation, and a gold standard study of GFR, such as isotopic measurement, was not performed. We did not have data regarding microalbuminuria for our patients. We used the manu- facturer recommendations for standardizing cystatin C, as it was not possible to use a cystatin C method already calibrated to the international standard or to conduct a calibration study with a reference laboratory, options that might be more precise. Our participants were a general population of patients with HF who were treated at a specific and multidisciplinary HF unit in a tertiary hospital; most patients were white and were referred from the car- diology department, resulting in relatively young men with HF of ischemic etiology and reduced LVEF. As such, the results we obtained cannot necessarily be extrapolated to a global HF population. Moreover, the almost exclusively white population limits the generalizations that can be made on the basis of our findings.
Conclusions
The new CKD-EPI-cystatin C and CKD-EPI-creatininecystatin C equations are useful for HF risk stratification and yield better measurements to predict death than the MDRD-4-IDMS and CKD-EPI equations, especially in patients with intermediate eGFR. These new equations may be considered for determining risk in HF patients with moderate renal insufficiency.
